Literature DB >> 23008195

Genetic variants in the catechol-o-methyltransferase gene are associated with impulsivity and executive function: relevance for major depression.

Dorottya Pap1, Xenia Gonda, Eszter Molnar, Judit Lazary, Anita Benko, Darragh Downey, Emma Thomas, Diana Chase, Zoltan G Toth, Krisztina Mekli, Hazel Platt, Antony Payton, Rebecca Elliott, Ian M Anderson, J F William Deakin, Gyorgy Bagdy, Gabriella Juhasz.   

Abstract

The catechol-o-methyltransferase (COMT) gene has been extensively investigated in depression with somewhat contradictory results but the role of impulsivity, as a possible intermediate phenotype in this disorder, has not been considered yet. In our study, four tagging SNPs in the COMT gene (rs933271, rs740603, rs4680, rs4646316) were genotyped in two independent population cohorts: Manchester (n = 1267) and Budapest (n = 942). First, we investigated the association between COMT genotypes, impulsivity, neuroticism and depression using haplotype trend regression, and constructed a model using structural equation modeling to investigate the interaction between these factors. Secondly, we tested the effect of executive function on this model in a smaller interviewed sample (n = 207). Our results demonstrated that COMT haplotypes were significantly associated with impulsivity in the combined cohort, showing the same direction of effects in both populations. The COMT effect on depressive symptoms (in subjects without history of depression) and on executive function (interviewed sample) showed the opposite pattern to impulsivity. Structural equation models demonstrated that COMT and impulsivity acted, both together (through neuroticism) and independently, to increase the risk of depression. In addition, better executive function also operated as a risk factor for depression, possibly though reduced ability to flexibly disengage negative emotions. In conclusion, variations in the COMT gene exert complex effects on susceptibility to depression involving various intermediate phenotypes, such as impulsivity and executive function. These findings emphasise that modeling of disease pathways at phenotypic level are valuable for identifying genetic risk factors.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23008195     DOI: 10.1002/ajmg.b.32098

Source DB:  PubMed          Journal:  Am J Med Genet B Neuropsychiatr Genet        ISSN: 1552-4841            Impact factor:   3.568


  6 in total

1.  Association of maternal and infant variants in PNOC and COMT genes with neonatal abstinence syndrome severity.

Authors:  Elisha M Wachman; Marie J Hayes; Richard Sherva; Mark S Brown; Hira Shrestha; Beth A Logan; Nicole A Heller; David A Nielsen; Lindsay A Farrer
Journal:  Am J Addict       Date:  2016-12-16

2.  Variations in opioid receptor genes in neonatal abstinence syndrome.

Authors:  Elisha M Wachman; Marie J Hayes; Richard Sherva; Mark S Brown; Jonathan M Davis; Lindsay A Farrer; David A Nielsen
Journal:  Drug Alcohol Depend       Date:  2015-07-08       Impact factor: 4.492

3.  Effects of acute dopamine precusor depletion on immediate reward selection bias and working memory depend on catechol-O-methyltransferase genotype.

Authors:  Mary Katherine Kelm; Charlotte A Boettiger
Journal:  J Cogn Neurosci       Date:  2013-08-12       Impact factor: 3.225

4.  Genetic polymorphisms of VIP variants in the Tajik ethnic group of northwest China.

Authors:  Jiayi Zhang; Tianbo Jin; Zulfiya Yunus; Xiaolan Li; Tingting Geng; Hong Wang; Yali Cui; Chao Chen
Journal:  BMC Genet       Date:  2014-09-30       Impact factor: 2.797

5.  Emotional stability is associated with the MAOA promoter uVNTR polymorphism in women.

Authors:  Ángel Rodríguez-Ramos; Juan Antonio Moriana; Francisco García-Torres; Manuel Ruiz-Rubio
Journal:  Brain Behav       Date:  2019-08-25       Impact factor: 2.708

6.  Cannabinoid Hyperemesis Syndrome Survey and Genomic Investigation.

Authors:  Ethan B Russo; Chris Spooner; Len May; Ryan Leslie; Venetia L Whiteley
Journal:  Cannabis Cannabinoid Res       Date:  2021-07-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.